Myasthenia Gravis Treatment Market Size is valued at USD 1.42 Bn in 2022 and is predicted to reach USD 2.71 Bn by the year 2031 at a 7.59% CAGR during the forecast period for 2023-2031.
Myasthenia gravis is an uncommon neuromuscular illness characterized by gradual weakness of the muscles of the face, neck, upper and lower body, and respiratory system. Producing antibodies against the acetylcholine receptor disrupts the regular flow of electrical signals from the nervous system to the muscles in this autoimmune illness. Myasthenia gravis is a condition that causes chronic weakening in the skeletal muscles due to damage to the neuromuscular junction.
Eye, facial, and swallowing muscles are particularly vulnerable. Investigative efforts are currently directed toward elucidating the mechanisms underlying autoimmune issues in MG and developing more effective diagnostic and therapeutic strategies to address them. Researchers have changed their approach as the market shifts its focus from weakening the immune system to rebalancing it. Although symptoms of myasthenia gravis can arise at any age, they tend to become more noticeable in men and women in their generation. Myasthenia gravis has no known treatment.
However, the myasthenia gravis therapy market is limited by the undesirable effects of the current medications. Increased risk of infection, weight gain, mood changes, and gastrointestinal difficulties are only some of the potential negative effects of drugs like corticosteroids and immune suppressants, which can impact patient compliance and limit market expansion. The COVID-19 pandemic has caused widespread chaos in the world's healthcare infrastructure.
The delay between diagnosis and treatment of myasthenia gravis during the epidemic had a major impact on patient outcomes. Doctors often ignored Myasthenia gravis and other non-emergency medical conditions during the epidemic. Delayed diagnosis and treatment may reduce the quality of life for people with myasthenia gravis by allowing the state to grow and worsen. As a result of supply chain problems brought on by the pandemic, players in the myasthenia gravis therapy industry saw their revenue stagnate.
Competitive Landscape
Some Major Key Players In The Myasthenia Gravis Treatment Market:
- Alexion Pharmaceutical Inc
- Grifols SA
- Avadel Pharmaceuticals plc
- Novartis AG
- Pfizer, Inc
- AbbVie Inc
- Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Bausch Health Companies Inc
- Shire plc
- AstraZeneca,
- Novartis AG,
- Zydus Lifesciences Limited,
- CSL Limited,
- Octapharma AG,
- Astellas Pharma Inc.,
- Kedrion, SpA.
- Others
Market Segmentation:
The myasthenia gravis treatment market is segmented based on treatment and end-use. AS per the treatment, the market is segmented into medication, surgery, and others. The end-use segment consists of hospitals, clinics, and others.
Based On The Treatment, The Medication Myasthenia Gravis Treatment Market Segment Is Accounted As A Major Contributor To The Myasthenia Gravis Treatment Market.
The medication coatings myasthenia gravis treatment market is expected to record a major global market share in 2022 because numerous diseases and ailments are addressed with various medications. Medication benefits include relief of pain, blood pressure reduction, and infectious disease treatment. Medication has dominated the market and will likely continue throughout the projection period. This is due to the fact that drugs can significantly suppress the immune system and control the accompanying symptoms. Treatment options include immunosuppressive medications like tacrolimus and cyclosporine and immunotherapies like Soliris eculizumab.
The Hospital Segment Is To Witness Growth At A Rapid Rate.
Hospitals are projected to grow rapidly in the global Myasthenia gravis treatment market due to this increase at a rate faster than any other predicted area. Hospitals have ready access to a big pool of potential patients, and there is a high demand for cutting-edge equipment to treat MG. The increased demand for MG diagnosis and treatment can be attributed to the abundance of available services in specialized clinics. The development of the pharmaceutical contract sales outsourcing market in the hospital's segment has myasthenia gravis market is being driven in large part by these subsets, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Myasthenia Gravis Treatment Market Holds A Significant Revenue Share.
The North American Myasthenia gravis treatment market is expected to register the greatest market share in revenue in the near future. The demand for myasthenia gravis treatments is predicted to grow because of the disease's high incidence, the uptick in autoimmune disease diagnosis, the existence of key firms offering novel medicines, and the availability of modern healthcare infrastructure. In addition, Asia Pacific is estimeted to grow rapidly in the global Myasthenia gravis treatment market. The market is expected a rapid growth due to the region's thriving industrial infrastructure, increasing funding for autoimmune illnesses, and the longstanding presence of domestic corporations. In addition, the region's growing number of contract manufacturing companies presents a significant opening for new businesses.
Recent Developments:
- In Aug 2023, The approval of Soliris (eculizumab) in Japan was granted for the treatment of generalised myasthenia gravis (gMG) in children who exhibit positivity for anti-acetylcholine receptor (AChR) antibodies and experience challenges in managing their symptoms through high-dose intravenous immunoglobulin (IVIG) or plasmapheresis. Soliris represents the sole targeted therapeutic intervention available in Japan for the treatment of generalised myasthenia gravis (gMG) specifically in the paediatric and adolescent population.
Myasthenia Gravis Treatment Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1.42 Bn |
|
Revenue Forecast In 2031 |
USD 2.71 Bn |
|
Growth Rate CAGR |
CAGR of 7.59 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Alexion Pharmaceutical Inc, Grifols SA, Avadel Pharmaceuticals plc, Novartis AG, Pfizer, Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Bausch Health Companies Inc, Shire plc, AstraZeneca, Novartis AG, Zydus Lifesciences Limited, CSL Limited, Octapharma AG, Astellas Pharma Inc., Kedrion, SpA., and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
